Impact of APOL1 polymorphism and IL-1β priming in the entry and persistence of HIV-1 in human podocytes.
Mikulak J
Retrovirology. 2016 Sep 6;13(1):63. doi: 10.1186/s12977-016-0296-3
Increased Infiltration of Natural Killer and T Cells in Colorectal Liver Metastases Improves Patient Overall Survival.
Donadon M
J Gastrointest Surg. 2017 May 23;21(8):1226-1236. doi: 10.1007/s11605-017-3446-6
Increased Frequency and Vasculogenic Potential of Endothelial Colony-Forming Cells in Patients with Kaposi’s Sarcoma.
Calcaterra F
J Invest Dermatol. 2017 Mar 10;137(7):1533-1540. doi: 10.1016/j.jid.2017.02.979
Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy.
Mariotti J
Blood Adv. 4(16):3900-3912. doi: 10.1182/bloodadvances.2020001620
Intrahepatic CD69(+)Vδ1 T cells re-circulate in the blood of patients with metastatic colorectal cancer and limit tumor progression.
Bruni E
J Immunother Cancer. 10(7)doi: 10.1136/jitc-2022-004579
Irrelevance of microsatellite instability in the epidemiology of sporadic pancreatic ductal adenocarcinoma.
Laghi L
PLoS One. 2012 Sep 21;7(9):e46002. doi: 10.1371/journal.pone.0046002
Immunotherapeutic early-phase clinical trials and malignant gliomas: A single-center experience and comprehensive immunophenotyping of circulating leukocytes.
Simonelli M
Neurooncol Adv. 2021 Nov 13;3(1):vdab160. doi: 10.1093/noajnl/vdab160
Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
Petrillo M
Ann Oncol. 2016 Jan 17;27(4):625-34. doi: 10.1093/annonc/mdw007
Inhibition of tumor-associated macrophages by trabectedin improves the antitumor adaptive immunity in response to anti-PD-1 therapy.
Belgiovine C
Eur J Immunol. 2021 Oct 8;51(11):2677-2686. doi: 10.1002/eji.202149379
Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4.
Colotta F
Science. 261(5120):472-5.